| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
Jatrorrhizine exhibits anti-plasmodial and anti-amoebic properties; its IC50 values against Entamoeba histolytica and Plasmodium falciparum are 82.7 µM and 3.15 µM, respectively [1]. In the brain, monoamine neurotransmitters are transported via hOCT2 (organic cation transporter 2), hOCT3 (plasma membrane monoamine transporter), and PMAT (plasma membrane monoamine transporter) [3]. Jatrorrhizine inhibits the absorption of 5-HT and NE in transfected hOCT2, hOCT3, and PMAT cells. Jatrophizine decreases hOCT2, hOCT3, and hPMAT-mediated 5-HT and NE uptake with IC50s of 0.1–1 μM for OCT2 and OCT3 and 1–10 μM (for PMAT) [3]. It also strongly inhibits PMAT-mediated MPP+ uptake with an IC50 of 1.05 μM. Two separate processes determine how neurotransmitters produced into the synaptic cleft are cleared. Antidepressants now in use frequently target Uptake-1, which includes the serotonin transporter (SERT). "SERT" can absorb [3H]5-HT with a high affinity but a poor capacity. The Uptake-2 transporter, which is regarded as a "NET" with low affinity but great capacity for uptaking [3H]5-HT into brain slices, is a crucial supplementary regulating system in monoamine clearance. At 25 μM and 50 μM, respectively, jatrorrhizine can dramatically reduce the absorption of 5-HT and NE in synaptosomes [3].
|
|---|---|
| ln Vivo |
In the tail suspension test (TST), jatrorrhizine chloride (ip; 5, 10, 20 mg/kg) significantly reduced immobility time compared with vehicle controls [2].
|
| Animal Protocol |
Animal/Disease Models: Male ICR albino mouse [2]
Doses: 5, 10, 20 mg/kg Route of Administration: intraperitoneal (ip) injection; 5, 10, 20 mg/kg Experimental Results: The immobility time in the tail suspension test was shortened. |
| References |
|
| Molecular Formula |
C20H20CLNO4
|
|---|---|
| Molecular Weight |
373.8301
|
| Exact Mass |
374.116
|
| CAS # |
6681-15-8
|
| Related CAS # |
Jatrorrhizine hydroxide;483-43-2;Jatrorrhizine;3621-38-3
|
| PubChem CID |
371256
|
| Appearance |
Orange to yellow solid powder
|
| LogP |
3.883
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
461
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JKMUUZMCSNHBAX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19NO4.ClH/c1-23-18-5-4-12-8-16-14-10-19(24-2)17(22)9-13(14)6-7-21(16)11-15(12)20(18)25-3;/h4-5,8-11H,6-7H2,1-3H3;1H
|
| Chemical Name |
2,9,10-trimethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium-3-ol;chloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~13.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.56 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.56 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6750 mL | 13.3751 mL | 26.7501 mL | |
| 5 mM | 0.5350 mL | 2.6750 mL | 5.3500 mL | |
| 10 mM | 0.2675 mL | 1.3375 mL | 2.6750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
